Our ReSOLVE platform enables a highly differentiated pipeline of small molecule therapeutics for highly validated innate immunity targets. Our lead programs target the inflammasome and nucleic acid sensing pathways. We have multiple programs in discovery and are pursuing a broad pipeline of additional targets.